Genentech, Inc.

Genetech, Inc.

23Andme, Inc.

F. Hoffmann-La Roche Ag

Germaine G Fuh

Chingwei Vivian Lee

Wei-Ching Liang

Sachdev Singh Sidhu

Christian Wiesmann

Hans-Peter Gerber

Frederic Fellouse

Patrick Koenig

Amin Famili

Karthikan Rajagopal

Jenny M Bostrom

James A Wells

Brian C Cunningham

Ross G Clark

Kenneth C Olson

Yan Wu

Robert F Kelley

Daniel Kirchhofer

Menno Van Lookeren Campagne

Tao Sai

Kelly M Loyet

Michael Terry Lipari

Joyce Lai

Henry Bernard Lowman

Mark X Sliwkowski

Gabriele Maria Schaefer

Anil Durgadas Bagri

Lauric Haber

Michael T Lipari

Sachdev S Sidhu

Mark S Dennis

Avi J Ashkenazi

Jo-Anne Hongo

Hanspeter Gerber

Dorothy French

Gretchen Frantz

Yu Chen

Robert Maurice Pitti

Liliana Soroceanu

David A Eberhard

Wei-Jen Chung

Beni B Wolf

Shruti Yadav

Mauro Poggio

Yujie Liu

Ping-Chiao Tsai

Claus Spitzfaden

Zahra Bahrami Dizicheh

Joel Benjamin

I-Ling Chen

Helga A Raab

Evgeny Varfolomeev

Scot A Masters

Heidi Ackerly

Shashank Bharill

Beni Wolf

Helga Raab

Scot Marsters

David Eberhard

Anil D Bagri

Gabriele Schaefer

Chingwei V Lee

Frederic A Fellouse

The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.

Optimized variants of anti-VEGF antibodies

The present disclosure relates to a ULBP6 binding protein that inhibits the interaction between ULBP6 and NKG2D, and methods of treating cancer with said ULBP6 binding protein.

Anti-ULBP6 antibodies

The invention provides dual specific antibodies capable of binding interleukin 4 (IL4) and interleukin 5 (IL5) and methods of making and using such antibodies. In general, the dual specific antibodies capable of binding IL4 and IL5 are generated by identification of a monospecific antibody having light chain variable region Vresidues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the Vof the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the Vof the antibody. The altered Vand the Vare expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected.

Dual specific antibodies for binding interleukin 4 (IL4) and interleukin 5 (IL5)

The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).

Methods of treating ocular disorders by administering a VEGF-binding antibody covalently linked to a hyaluronic acid polymer

The invention provides multispecific antibodies and methods of making and using such antibodies.

Multispecific antibodies

The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.

Anti-HtrA1 antibodies and methods of use thereof

Conjugates comprising a vascular endothelial growth factor (VEGF) antibody and a hyaluronic acid polymer

The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.

Anti-CD3 antibodies and methods of use

Polynucleotides encoding optimized variants of anti-VEGF antibodies

Optimized variants of anti-vegf antibodies and methods of use thereof in treatment

The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region Vresidues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the Vof the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the Vof the antibody. The altered Vand the Vare expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.

Dual specific antibodies

The invention provides multispecific antibodies and methods of making and using such antibodies. In general, the multispecific antibodies are made by methods involving the steps of altering the nucleic acid sequence encoding the light chain variable domain (V) of an antibody that binds a first epitope, and selecting a multispecific antibody capable of binding the first and a second epitope.

Growing community of inventors

Pacifica, CA, United States of America

Germaine G Fuh